Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
39.29 USD +6.19% Intraday chart for Spyre Therapeutics, Inc. +14.75% +82.57%
05-13 Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating MT
05-09 Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spyre Therapeutics, Inc. Announces Board Changes
CI
Aeglea BioTherapeutics, Inc. will Change its Name to Spyre Therapeutics, Inc
CI
Aeglea BioTherapeutics Changes Name to Spyre Therapeutics; CEO Appointed
MT
Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer
CI
Aeglea BioTherapeutics, Inc. Announces Executive Changes
CI
Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer
CI
Aeglea BioTherapeutics Appoints Scott Burrows as CFO
MT
Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
CI
Aeglea BioTherapeutics, Inc. Announces Executive Changes
CI
Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer
CI
Aeglea BioTherapeutics, Inc. Announces Executive Changes
CI
Aeglea BioTherapeutics Cuts 15% of Workforce, Halts Development Programs; COO to Leave; Shares Fall
MT
Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer
CI
Anticipation Ahead of Powell's Speech Supports Modest Rise in Exchange Traded Funds Premarket Wednesday
MT
Aeglea BioTherapeutics Names Jeffrey Goldberg Chief Executive Officer
MT
Aeglea BioTherapeutics, Inc. Appoints Jeffrey M. Goldberg as President, and Member of the Board of Directors
CI
Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes
CI
Aeglea BioTherapeutics Promotes Linda Neuman to Chief Medical Officer
MT
Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer
CI
Aeglea BioTherapeutics to Restructure; Cuts 25% of Headcount, Appoints Jim Kastenmayer as Interim CEO
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. News Spyre Therapeutics, Inc.
  5. Insiders